- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02229877
A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)
A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Must be informed of the nature of the study and have provided written informed voluntary consent;
Able to speak, read, and understand English;
Healthy males or females, of any race, between 18 and 55 years of age, inclusive;
Body mass index (BMI) >18.5 and <32.0 kg/m2 and weigh 50 - 100 kg;
In good general health ;
Non-smokers for at least 5 years;
If a female of child-bearing potential (i.e., have not undergone a hysterectomy or bilateral oophorectomy) or not post-menopausal (defined as no menses for at least 12 months), agree to use 2 forms of acceptable birth control; or if a male, they and/or their partner of child-bearing potential agree to use 2 forms of acceptable birth control;
Exclusion Criteria:
Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease;
Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication;
Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hay fever during the time of the year that dosing will be taking place;
History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton pump inhibitors within 12 months of Screening;
Have a positive screening test for Helicobacter pylori;
QTcB >450 msec in males or >460 msec in females;
Known or suspected hypersensitivity or allergic reaction to any of the components of gefapixant or omeprazole capsules;
If female, is pregnant or breast feeding, or has a positive pregnancy test pre dose;
Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of the first dose of study drug;
Chronic use of any systemic medications; use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications including antacids, high dose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug;
Past or current history or evidence of drug or alcohol abuse, use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or pre dose;
Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration;
Positive urine cotinine test at Screening or Day 1 pre dose;
Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody;
Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication;
Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Gefapixant + Omeprazole
Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days + Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days |
40 mg oral capsules administered twice daily for 8.5 days
Other Names:
Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
Other Names:
Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
Other Names:
Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Intragastric pH on gefapixant PK
Time Frame: At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose
|
Analysis of variance (ANOVA) will be performed on log normal-transformed Cmax and AUC0-t values to determine the extent of a drug interaction, if any, of omeprazole on the plasma gefapixant PK parameters.
These analyses will be conducted for both fed and fasted conditions and the 50 mg and 150 mg treatments.
|
At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Fasting on gefapixant PK
Time Frame: At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose
|
ANOVA will be performed on log normal-transformed Cmax and AUC0-t values to determine if fasting affects plasma gefapixant PK parameters.
|
At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7264-011
- AF219-011 (OTHER: Afferent Pharmaceuticals)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Omeprazole
-
Damascus HospitalWithdrawnPeptic Ulcer Hemorrhage | Marginal Ulcer | Gastroduodenal UlcerSyrian Arab Republic
-
MetroHealth Medical CenterCompleted
-
University of LouisvilleBausch Health Americas, Inc.CompletedGastroesophageal Reflux Disease | GastroparesisUnited States
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
Aboca Spa Societa' AgricolaUniversity of Roma La Sapienza; Doppel Farmaceutici; BMR GenomicsCompleted
-
Yvonne RomeroBausch Health Americas, Inc.CompletedErosive EsophagitisUnited States
-
Nekkar Lab SrlOpera CRO, a TIGERMED Group CompanyRecruitingGastroesophageal Reflux Disease (GERD)Italy, Romania